DrugDashboards

Octreotide Acetate

Octreotide Acetate · Kit · Intramuscular · Teva Pharmaceuticals, Inc.

NDC 00480-9262-08 · 1 KIT in 1 KIT * 8 mL in 1 VIAL, SINGLE-DOSE * 2 mL in 1 SYRINGE · ANDA · View full market →

The short version

Just 3 companies supply this market — thin enough that a single exit would be felt immediately. 4 Class II recalls hit this product in the past year (Teva Pharmaceuticals USA, Inc).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Medicare Part B pays (ASP+6%)$208.10per billing unit (1 MG)HCPCS J2353 · Jul 1, 2026
  • Part D plans paid (avg)$8.81per dosage unitgross, before rebates — matched by drug name · 2024

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$5,972.45
Reported to Texas DSHS · 2026 annual filing · Teva Pharmaceuticals, Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 1 MG
$208.095
HCPCS J2353 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$842,621
203 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.2%chance of a new FDA shortage posting for octreotide acetate (other) in the next 90 days

4 Class I/II recall(s) in 12 months · sole-source market · price up 4% YoY

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
ANDA210317
TE code
AB
Approval date
Dec 5, 2023
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · OngoingApr 24, 2026
    Teva Pharmaceuticals USA, Inc — Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
  • Class II · OngoingMar 17, 2026
    Teva Pharmaceuticals USA, Inc — Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
  • Class II · OngoingMar 17, 2026
    Teva Pharmaceuticals USA, Inc — Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
  • Class II · OngoingMar 17, 2026
    Teva Pharmaceuticals USA, Inc — Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

Manufacturers of Octreotide Acetate (Kit)

LabelerStrengthFirst seenLast seen
Mylan Institutional LLCJul 15, 2026Sep 3, 2026
Novartis Pharmaceuticals CorporationJul 15, 2026Sep 3, 2026
Teva Pharmaceuticals, Inc.Jul 15, 2026Sep 3, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Octreotide Acetate — NDC 00480-9262-08," retrieved September 3, 2026, https://drugdashboards.com/drug/00480926208.

Free to cite with attribution — see how the data is put together.